VR Logo

Ayala Pharmaceuticals Inc. (AYLA) download report


Healthcare | Biotechnology & Pharma Research

Ayala Pharmaceuticals Inc. (AYLA) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers.

IPO Date: 08-May-2020

Pres, CEO & Director: Dr. Roni Mamluk M.D., Ph.D.

CFO, Sec. & Treasurer: Mr. Yossi Maimon CPA, M.B.A., CPA, MBA

Listing: NASDAQ: AYLA

Country: Israel

Headquarters: Rehovot,

Website: https://www.ayalapharma.com

Key Facts

Market cap: $15.67 Mln

Revenue (TTM): $2.99 Mln

Earnings (TTM): $-40.71 Mln

Cash: $27.05 Mln

Total Debt: $0.47 Mln

Insider's Holding: 31.29%

Liquidity: Low

52 Week range: $0.96 - 14.95

Shares outstanding: 14,085,300

Stock Performance

Time Period Ayala Pharmaceuticals (AYLA) S&P BSE Sensex S&P Small-Cap 600
YTD-87.07-9.18-18.78
1 month-27.63-4.78-8.00
3 months-72.36-9.66-13.65
1 Year-89.210.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Ayala Pharmaceuticals (AYLA) S&P Small-Cap 600 S&P BSE Sensex
2021-22.6425.2721.99